Biosimilars Legislation in Ireland Scrutinised in DH

With the growing costs of new medicines coming to market, biologics and biosimilars look to be a promising hope for the healthcare industry in providing cheaper alternatives.

The Department of Health in Ireland is assessing the area of biosimilar medicines with the aim of developing policies that would support the uptake of such medicines as they become available.

An agreement with the Irish Pharmaceutical Healthcare Association (IPHA), which runs to 2020, is projected to result in savings of €600 million from IPHA companies, with €150 million anticipated from non-IPHA companies over the lifetime of the deal.

Included in the agreement is a 30% reduction in the price of biologic medicines when a biosimilar medicine enters the market, with the issue of affordability central to the new agreement.

Read the full article here.

Tagged with

Published 3. November 2016 in News Ireland